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Purpose: This article reviews the effects of the increase in bacterial resistance on the treatment 
of ocular infections.
Design: Interpretive assessment.
Methods: Literature review and interpretation.
Results: Ocular bacterial infections include conjunctivitis, keratitis, endophthalmitis, blepharitis, 
orbital cellulitis, and dacryocystitis. Treatment for most ocular bacterial infections is primarily 
empiric with broad-spectrum antibiotics, which are effective against the most common bacteria 
associated with these ocular infections. However, the widespread use of broad-spectrum 
systemic antibiotics has resulted in a global increase in resistance among both Gram-positive 
and Gram-negative bacteria to a number of the older antibiotics as well as some of the newer 
fluoroquinolones used to treat ophthalmic infections. Strategies for the prevention of the increase 
in ocular pathogen resistance should be developed and implemented. In addition, new antimi-
crobial agents with optimized pharmacokinetic and pharmacodynamic properties that have low 
toxicity, high efficacy, and reduced potential for the development of resistance are needed.
Conclusions: New antimicrobial agents that treat ocular infections effectively and have a low 
potential for the development of resistance could be a part of strategies to prevent the global 
increase in ocular pathogen resistance.
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Introduction
Ophthalmic infections can cause damage to structures of the eye, which can lead to 
vision loss and even blindness if left untreated.1 The effective use of antibiotics to treat 
ophthalmic infections requires an understanding of the disease and the pharmacokinetics 
and pharmacodynamics of the drugs used for the treatment.1,2 The most common ocular 
infection seen by primary care physicians worldwide is bacterial conjunctivitis, which 
is self-limiting and largely presents as an acute infection.3,4 Bacterial keratitis, an infec-
tion of the cornea often associated with contact lens wear, ocular trauma, or ocular 
surface disease, is less common but poses a risk of loss of vision.5–8 Endophthalmitis 
is a rare but potentially sight-threatening infective complication of intraocular surgery 
(primarily cataract), intravitreal injections, and ocular trauma.9,10 Bacterial blepharitis is 
an inflammation of the eyelids, particularly at the lid margins, that may be associated 
with a low-grade staphylococcal bacterial infection.11 Orbital cellulitis and other 
periorbital infections can be caused by a variety of organisms, including bacteria, 
and occurs as a complication of surgery, nonsurgical trauma, or the retention of a 
foreign body.12 Dacryocystitis, or infections of the lacrimal sac, are common at all Clinical Ophthalmology 2009:3 508
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ages and occur due to acquired or congenital obstruction of 
nasolacrimal duct.13 Although treatment guidelines for these 
ocular infections recommend that laboratory culture and 
smear tests be conducted, when possible, for determination 
of the causative pathogens,14 in practice the initial choice 
of antibiotic therapy is generally made without knowing 
the identity or susceptibility of the ocular pathogen.1,9,15,16 
Broad-spectrum antibiotic therapy for bacterial infections is 
initially used in order to prevent a decline in vision or perma-
nent vision loss that may require surgical intervention.9,16,17 
Endophthalmitis, bacterial keratitis, and orbital cellulitis 
require aggressive initial broad-spectrum antibiotic therapy, 
which can subsequently be tapered or modified after the 
results from laboratory culture and smear tests are obtained.18 
In this context, it must be noted that most ophthalmic antibi-
otics are approved for bacterial conjunctivitis only, with few 
indicated for keratitis and none for endophthalmitis.19
Several therapeutic classes of antibiotic agents are 
available for ophthalmic indications. These agents differ in 
their mechanism of action, coverage of important pathogens, 
and bactericidal versus bacteriostatic effects. The penicillins, 
cephalosporins, aminoglycosides, and fluoroquinolones are 
bactericidal agents (ie, kill bacteria)20 and are generally 
used to treat ocular infections. Bacteriostatic drugs 
like tetracyclines, macrolides, chloramphenicol, and 
sulfonamides, which inhibit bacterial growth, are used 
in cases in which there is a specific benefit or an allergy 
issue. Antibiotics can be used systemically or topically to 
control ocular infection. Topically applied antibiotics are 
more effective in achieving rapid, high concentrations of the 
antibiotic at the site of infection compared to systemically 
administered antibiotics. Frequent or inappropriate, 
systemic long-term use of an antibiotic may result in the 
development of bacterial antibiotic resistance. Therefore, 
topical administration of antibiotics may be a better 
choice, although the occurrence of drug resistance with 
topical antibiotics used for prolonged periods has been 
reported.1 Ophthalmic antibiotics are generally formulated 
as solutions or suspensions, but some are also available as 
ointments (eg, erythromycin, polymyxin, or bacitracin). 
Ointments theoretically provide prolonged exposure, since 
they do not get removed from the site of infection as rapidly 
as ophthalmic solutions/suspensions do because of rapid 
tear film turnover.1 However, hydrophilic antibiotics often 
crystallize within the ointment base, which may impact their 
release, available concentration, and effectiveness.1 Other 
factors that affect the exposure of ocular drugs include the 
integrity of the corneal epithelial barrier, inflammation of 
the ocular tissues, and the microtoxicity associated with 
the use of preservatives.1 Thus, the clinician may choose 
from a number of formulations of agents based on the 
location and severity of the infection, comorbidities, and the 
safety and tolerability of the antibiotic as well as bacterial 
susceptibility.
Rapid use of antibiotics for severe ocular infections is 
routine in ophthalmic practice, as pathogenesis of ocular 
bacteria results in release of toxins and degradative enzymes 
that can damage the integrity of ocular tissues and cause 
sight-damaging sequelae. Although older ophthalmic 
antibiotics such as chloramphenicol, sulfonamides, polymyxins, 
bacitracin, and aminoglycosides and early-generation 
fluoroquinolones are still prescribed, they are less effective 
than the advanced-generation fluoroquinolones for treating 
ocular infections because of a limited spectrum of activity 
and/or the development of pathogen resistance.21,22 The 
advanced-generation fluoroquinolones (eg, moxifloxacin and 
gatifloxacin) have a broader spectrum of activity and are more 
effective against common ocular pathogens.23
The development of bacterial resistance to specific 
antibiotics is an important consideration for clinicians 
treating ocular infections. Bacterial resistance has been 
emerging worldwide, likely due to widespread and 
inappropriate dosing of broad-spectrum antibiotics for 
systemic infections, exacerbated by inadequate compliance to 
full treatment duration.24 Of note, the Ocular Tracking Resis-
tance in the U.S. Today (TRUST) program, which annually 
evaluates the in vitro susceptibility of Staphylococcus aureus, 
Streptococcus pneumoniae, and Haemophilus influenzae to 
a number of ophthalmic antibiotics in national samples of 
ocular isolates, reported a 12.1% increase in the incidence of 
methicillin-resistant S. aureus (MRSA) strains from January 
2000 to December 2005, with more than 80% of MRSA 
resistant to fluoroquinolones.25,26 While these numbers are 
alarming, one limitation of studies on the emergence of 
resistance among ocular pathogens is that the determina-
tion of bacterial susceptibility to ophthalmic antibiotics is 
typically based on systemic drug exposure breakpoints, 
the concentrations at which bacterial isolates are deemed 
susceptible or resistant to a particular drug.27,28 The data used 
to determine breakpoints are derived from systemic dosing and 
the average concentration of drugs in tissues after systemic 
administration. Since topical administration produces a higher 
concentration of antibiotic in ocular tissues than that achieved 
following systemic therapy, these breakpoints, defined by the 
Clinical and Laboratory Standards Institute (CLSI), do not 
apply.27 Nevertheless, as discussed later in this review, there Clinical Ophthalmology 2009:3 509
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are many reports of clinical treatment failure due to ocular 
pathogen drug resistance. These reports highlight the need to 
reevaluate and implement improved treatment guidelines for 
the prevention of pathogen resistance to ocular anti-infective 
therapies,26,27 and the need to develop new antibiotics with 
greater efficacy, lower toxicity, and lower resistance potential 
than older agents.29
Ocular infections and current 
treatment options
Bacterial conjunctivitis
Bacterial conjunctivitis, or red eye, which involves 
inflammation of the conjunctival mucosa, is more common 
in young children and the elderly than in other age groups.3 
The etiology of conjunctivitis can be allergic, toxic, or 
infectious. Symptoms of bacterial conjunctivitis include a 
purulent discharge around the eye, hyperemia, and a burning 
or stinging sensation.3,15 The most common causal pathogens 
in bacterial conjunctivitis are S. aureus, S. pneumoniae, and 
H. influenzae. Staphylococcus epidermidis, Enterococcus 
spp., Moraxella spp., streptococci viridans group, Escherichia 
coli, Serratia marcescens, Pseudomonas aeruginosa, and 
Proteus mirabilis have also been isolated less frequently 
from bacterial conjunctivitis samples.3,30,31 Gram-positive 
pathogens accounted for 52.5% of positive cultures, 72.1% 
of which were S. aureus (Table 1).31 Staphylococci infections 
are more common in adults, while S. pneumoniae and 
H. influenzae are more common in children.31
Although clinical resolution of bacterial conjuncti-
vitis occurs without any treatment in most patients by 
7 days, treatment with broad-spectrum topical antibiotics 
accelerates the rate of clinical resolution and decreases 
the risk of contagious spread.4,15,30,32 Topical antibiotics 
indicated for bacterial conjunctivitis include aminoglyco-
sides (eg, gentamicin and tobramycin), polymyxin-based 
combinations (eg, polymyxin B sulfate and trimethoprim), 
azithromycin, fluoroquinolones (eg, ciprofloxacin, 
levofloxacin, ofloxacin, moxifloxacin, and gatifloxacin), 
and, outside of the United States, chloramphenicol.4,30
Bacterial keratitis
Bacterial keratitis is a potentially devastating ocular infection 
that may occur when the corneal epithelial barrier is 
compromised due to injury or trauma, leading to ulceration 
and infiltration of inflammatory cells.33 Infection largely 
involves Gram-positive S. aureus, S. epidermidis, and several 
Streptococcus and Bacillus spp., as well as Gram-negative 
bacteria like P. aeruginosa, S. marcescens, Moraxella 
lacunata, Microbacterium liquefaciens, and H. influenzae. 
Immediate diagnosis and treatment are important to avoid 
vision-threatening outcomes, including corneal scarring or 
perforation.1 Clinical signs and symptoms include mild to 
severe ocular pain, photophobia, decreased vision, tearing, 
discharge, inflammation, focal white opacity in the corneal 
stroma (infiltrate), staining of the area (indicating an 
epithelial defect), corneal thinning, stromal edema, mild to 
severe anterior chamber reaction, and eyelid edema.7,8,34 The 
most common predisposing factors for bacterial keratitis are 
ocular trauma, contact lens wear (especially extended wear), 
ocular surface disease, and prior ocular surgery.7,34
Standard treatment of bacterial keratitis is a combina-
tion of cefazolin and tobramycin or an aminoglycoside such 
as gentamicin and a second-generation cephalosporin such 
as cefuroxime to avoid aminoglycoside retinal toxicity.11 
Ciprofloxacin 0.3%, ofloxacin 0.3%, and levofloxacin 1.5% 
are indicated in the United States for the treatment of corneal 
ulcer;35–37 monotherapy with fluoroquinolones may now be 
the preferred treatment, especially if the infection is associ-
ated with wearing contact lenses.7 However, the emerging 
resistance of Gram-positive organisms to older agents and 
fluoroquinolones has underscored the importance of the 
clinical practice recommendation to culture all corneal ulcers 
before antimicrobial treatment.16 Newer fluoroquinolones 
are therefore recommended for initial therapy of bacterial 
Table 1 Prevalence of most common isolates from patients with bacterial conjunctivitis recovered within the 2-year period31
  1994–1995 1996–1997 1998–1999 2000–2001 2002–2003 Total
Gram-positive 
  Staphylococcus aureus 
  Streptococcus pneumoniae 
  Streptococcus viridans group
166 (54.2%) 
108 (65.0%) 
18 (10.8%) 
19 (11.6%)
152 (56.5%) 
114 (75.0%) 
14 (9.2%) 
6 (3.9%)
128 (50.4%) 
89 (69.5%) 
21 (16.4%) 
10 (7.8%)
88 (47.6%) 
69 (78.4%) 
11 (12.5%) 
6 (6.8%)
121 (50.4%) 
92 (76.0%) 
16 (13.2%) 
6 (5.0%)
655 (52.5%) 
472 (72.1%) 
80 (12.2%) 
47 (7.2%)
Gram-negative 
  Haemophilus influenzae 
  Pseudomonas aeruginosa 
  Proteus mirabilis
140 (45.8%) 
63 (45.0%) 
16 (11.4%) 
15 (10.7%)
117 (43.5%) 
53 (45.3%) 
8 (6.8%) 
8 (6.8%)
126 (49.6%) 
62 (49.2%) 
11 (8.7%) 
8 (6.3%)
97 (52.4%) 
50 (51.5%) 
5 (5.2%) 
3 (3.1%)
119 (49.6%) 
48 (40.3%) 
17 (14.3%) 
7 (5.9%)
599 (47.8%) 
276 (46.1%) 
57 (9.5%) 
41 (6.8%)Clinical Ophthalmology 2009:3 510
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keratitis to avoid progression of the ocular infection to corneal 
perforation, endophthalmitis, and even loss of the eye.33
endophthalmitis
Endophthalmitis is a rare but potentially sight-threatening 
complication of intraocular surgery, intravitreal injections, 
and ocular trauma.9,38,39 The incidence of endophthalmitis 
following cataract surgery has increased over the last decade 
despite many technical advances and faster visual recovery,40 
and ranges from 0.2% to 0.7% in the United States and 
Europe.10,41,42 The risk for occurrence of endophthalmitis 
following intravitreal injection of corticosteroids has been 
estimated to be 0.8% from noninfectious causes and 0.6% 
to 1.6% from infectious causes.37,43–46 Risk factors for endo-
phthalmitis can be preoperative (blepharitis, lachrymal duct 
obstruction, contact lens use, and secondary intraocular 
lens implantation), intraoperative (inadequate eyelid or 
conjunctival disinfection, surgery lasting for more than 1 hour, 
loss of vitreous humor, or unplanned ocular penetration) or 
postoperative (wound abnormalities, inadequately buried 
sutures, suture removal, and vitreous incarceration in the 
surgical wound).47 Coagulase-negative Staphylococcus 
(CoNS) and Bacillus spp. are the most common pathogens 
of posttraumatic endophthalmitis.48 A postcataract study 
with 497 patients with endophthalmitis showed that more 
than 90% of the isolates were Gram-positive, mostly CoNS, 
and that the in vitro susceptibility profiles of these pathogens 
had changed over a decade.49 A review of 1182 consecutive 
open-globe injuries identified 10 patients with culture-proven 
endophthalmitis. Endophthalmitis-related isolates from these 
patients included Streptococcus spp. (46.2%), CoNS (23.1%), 
and Bacillus cereus (15.4%).48
Intravitreal antibiotics including vancomycin and an 
aminoglycoside or third-generation cephalosporin are used 
to treat bacterial endophthalmitis, while vitrectomy may 
be needed for severe cases.9 Since the causal organisms of 
endophthalmitis may often be the patient’s own conjunctival 
bacterial flora, many of the routinely used prophylactic 
measures aim to decrease the number of ocular bacteria 
before and after surgery.50,51 Prophylaxis for endophthalmitis 
includes ocular antibiotics and anti-inflammatory agents 
used in the pre-, peri-, and postoperative period,10,52 as well 
as intracameral use of cefuroxime at the end of surgery.53 
Gatifloxacin and moxifloxacin are routinely administered 
topically along with the antiseptic povidone-iodine before 
cataract removal.11,52 Topical moxifloxacin was shown to 
reduce the incidence of endophthalmitis to less than 0.1% in a 
retrospective, observational case review of 20,013 patients,50 
while intracameral use of cefuroxime at the end of surgery 
also reduced the occurrence of endophthalmitis to less than 
0.1%.53 More than 75% of ophthalmologists in the United 
States and Europe use preoperative antibiotics, among which 
the fluoroquinolones have grown increasingly popular.48,54,55 
Neither topical antibiotics nor intracameral cefuroxime are 
indicated for endophthalmitis.
Bacterial blepharitis
Bacterial blepharitis is an infection and inflammation of the 
eyelid margin associated with hyperemia with crusting on 
the eyelashes. The most common complications of untreated 
blepharitis are abnormal eyelash growth (ie, trichiasis), 
scarring of the eyelids, and injury to the cornea due to 
constant irritation, which may cause small corneal ulcers.56 
The most common causal pathogens for bacterial blepharitis 
are S. aureus and CoNS.56,57 The standard of care in bacterial 
blepharitis is antibiotic therapy along with lid scrubs and 
hot compresses. Ointments of erythromycin, bacitracin, or 
polymyxin have routinely been used.11 Antibiotic therapy in 
chronic bacterial blepharitis has to be optimized in order to 
avoid the development of antibiotic resistance due to long-term 
antibiotic use.11 In cases where ocular rosacea is a contributing 
factor to eyelid inflammation in bacterial blepharitis, oral 
tetracycline, doxycycline, or minocycline is also used.11
Periorbital and orbital cellulitis
Preseptal (periorbital) and postseptal (orbital) cellulitis are 
potentially vision-threatening bacterial infections of the 
periocular tissue. While preseptal cellulitis involves only 
the lid structures and periorbital tissues anterior to the 
orbital septum, postseptal cellulitis involves tissues behind 
the septum, and it is seen more commonly in children and 
adolescents than adults. Routes of infection include trauma, 
bacteremia, sinusitis, and upper respiratory infections. 
Signs and symptoms include swelling of the eye, pain, 
fever, erythema, impaired ocular motility, afferent pupillary 
defect, proptosis, and visual loss. Sinus radiographs, 
computed tomography, magnetic resonance imaging, and 
orbital ultrasonography are used for prognosis. The most 
common pathogen is H. influenzae. If there is an associated 
local wound, the pathogens may include S. aureus and 
Streptococcus pyogenes.58
Traditionally, azithromycin, cephalosporins, penicillins, 
and clindamycin have been used in oral form to provide 
broad-spectrum coverage against staphylococci, streptococci, 
and anaerobes associated with ocular sinusitis (nonviral) 
and orbital cellulitis.59 Alternatively, vancomycin or other Clinical Ophthalmology 2009:3 511
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intravenous antibiotics may be used.58,59 Optic nerve function 
is monitored every 4 hours (through pupillary reactions, 
visual acuity, color vision, and light brightness appreciation). 
Treatment, which may be modified according to laboratory 
results, typically lasts 7 to 10 days.58 Surgery is indicated if 
there is a lack of response to antibiotic treatment or other 
complications occur.1
Dacryocystitis
Dacryocystitis is a painful inflammation of the lacrimal sac 
resulting from congenital or acquired obstruction of the 
nasolacrimal duct. In adults, it is idiopathic or the result 
of an obstruction from infection, trauma, or dacryolith, or 
rarely a neoplasm.60 In dacryocystitis, the medial lower lid 
location is protruding, tender, and painful, with discharge 
and tearing. The most common isolates in dacryocystitis 
are P. aeruginosa, S. aureus, Enterobacter aerogenes, 
Citrobacter, S. pneumoniae, E. coli, and Enterococcus 
spp.61,62 Treatment of dacryocystitis includes hot packs 
with topical and systemic antibiotics to cover penicillinase-
producing staphylococcal organisms.6 Clearing the drainage 
system, along with treatment with parenteral and topical 
antibiotics until the infection clears, is the standard therapy 
for dacryocystitis.1 Topical antibiotic treatment includes 
ceftazidime, ciprofloxacin, and cefuroxime.62 A higher 
incidence of Gram-negative organisms, particularly 
Pseudomonas, may indicate a trend in dacryocystitis 
infections towards antibiotic resistance.62 It is important to 
modify the antibiotic therapy based on a patient’s response, 
laboratory culture, and sensitivity results to avoid the devel-
opment of drug-resistant chronic dacryocystitis.
Bacterial resistance  
in ocular infections
The emerging resistance of ocular pathogens to topical 
antimicrobial agents is a worldwide problem. The emer-
gence of bacterial resistance is influenced by characteristics 
of the pathogens, antibiotic-prescribing practices including 
the widespread use of systemic antibiotics, and health care 
guidelines.63 Data from the worldwide surveillance programs 
TRUST, GLOBAL, PROTEKT, ARM, SENTRY, ABC, 
and TSN64–69 document widespread resistance among the 
pathogens commonly responsible for systemic infections to 
many systemically administered antimicrobial agents.63,70,71 
Worldwide, S. pneumoniae has a 20% to 30% resistance rate 
to penicillin and a 25% to 35% resistance rate to macrolides 
and azalides.72,73 In addition, 20% to 30% of H. influenzae 
isolates produce β-lactamase, which confers resistance to 
ampicillin.72,73 Ocular pathogen resistance to antimicrobial 
agents is increasing in parallel with an increase in antibiotic 
resistance in general, and is a major concern, since it narrows 
treatment choices for the management of common ocular 
infections.74 Surveillance studies that document resistance 
among ocular pathogens include Ocular TRUST25,26 and 
analyses of data from The Surveillance Network (TSN).27
increasing bacterial resistance 
in conjunctival infections
Studies of bacterial isolates from ophthalmic infections have 
reported an increase in resistance to the older fluoroquino-
lone ciprofloxacin among S. aureus and the emergence of 
methicillin-resistant S. aureus (MRSA).26,65,74,75 A nearly 
3-fold increase in resistance to the older fluoroquinolones, 
including ciprofloxacin, among S. aureus isolates from con-
junctival swabs was noted over a 10-year period (1994 to 
2003), and the prevalence of MRSA among S. aureus isolates 
increased from 4.4% to 42.9% (P = 0.001).31 Of note, a recent 
study of multidrug-resistant isolates (total of 1324 isolates 
examined) from clinical trials in bacterial conjunctivitis 
reported a significant prevalence of ciprofloxacin resistance 
in conjunction with methicillin resistance - 65% of MRSA 
isolates and 47% of methicillin-resistant S. epidermidis 
isolates were also ciprofloxacin resistant.76 Resistance has 
also increased to erythromycin and oxacillin among Gram-
positive isolates and to trimethoprim/sulfamethoxazole 
(TMP/SMX) among Gram-negative isolates.31 In a bacterial 
conjunctivitis study in pediatric patients (N = 428, ages 2 to 
36 months), antibiotic resistance rates were high for pneu-
mococcal isolates (penicillin, 60%; TMP/SMX, 38%; 
erythromycin, 23%; tetracycline, 18%; clindamycin, 9%).77 
Multidrug resistance was reported in 20% of pneumococcal 
isolates, highlighting the potential role of conjunctivitis in 
the spread of antibiotic-resistant pathogens.77
In a phase III study of resistance to azithromycin and 
moxifloxacin among conjunctival isolates, the MIC90 
for tested organisms was below the CLSI-established 
resistance breakpoints for moxifloxacin and above the 
resistance breakpoints for azithromycin (3-fold higher for 
H. influenzae; 128-fold higher for S. epidermidis; 16-fold 
higher for S. pneumoniae; 128-fold higher for S. aureus).78 
In a killing kinetic study, moxifloxacin exhibited a faster speed 
of bacterial kill than other nonfluoroquinolone antibiotics 
(tobramycin, gentamicin, polymyxin B/trimethoprim, or 
azithromycin) in S. aureus, S. pneumoniae, and H. influenzae 
isolated from conjunctival swabs.79 These studies indicate that 
advanced-generation fluoroquinolones may kill bacteria more Clinical Ophthalmology 2009:3 512
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rapidly, leading to a faster resolution of ocular infection in 
the eye than with older topical ocular antibiotics and thereby 
reducing the risk of ocular drug resistance.79
The trend of growing ocular bacterial antibiotic 
resistance was also seen in a decrease in in vitro sus-
ceptibility to gentamicin and tobramycin in corneal and 
conjunctival samples. Susceptibility decreased among all 
tested pathogens from 88% to 95% at the beginning of the 
study to 50% to 80% at the end of the 15-year surveillance 
period in 2000.80 Ninety percent of bacteria in the cornea and 
95% of bacteria in the conjunctiva remained susceptible to 
ciprofloxacin, norfloxacin, and ofloxacin in 2000.80 A subse-
quent 2-year Brazilian study (N = 219) also concluded that 
advanced-generation fluoroquinolones, such as gatifloxacin 
and moxifloxacin, were more active than older antibiotics 
against Gram-positive bacteria.81 It is therefore important 
to treat bacterial conjunctivitis rapidly to decrease disease 
transmission, shorten symptom duration, and minimize the 
emergence and spread of resistant bacteria.79
increasing bacterial resistance in keratitis 
infections
An increase in bacterial resistance has also been observed 
for keratitis infections. A review of resistance patterns 
over 2 consecutive 10-month periods found an increase 
in resistance rates among Gram-positive bacterial keratitis 
isolates to ciprofloxacin, cefazolin, and gentamicin.82 
Increased resistance to these commonly used antibiotics 
indicated a need for close follow-up after initial treatment and 
suggested maintaining a low threshold for selecting alterna-
tive therapy.82 Among Gram-negative bacteria, a retrospective 
chart review of 1312 bacterial isolates from 1984 through 1999 
found a significant (P = 0.0019) increase in chloramphenicol 
resistance, suggesting that chloramphenicol is unlikely to 
provide prophylactic coverage for Gram-negative ocular 
infections.83 In a study of 291 patients with presumed bac-
terial keratitis, 68% were culture positive, of which 83% 
of cultures were Gram-positive, 17% Gram-negative, and 
2% polymicrobial.6 In a 5-year retrospective review of 
patients (N = 131) with bacterial keratitis, P. aeruginosa 
and S. aureus were the most common isolates, and 15.4% 
of S. aureus isolates were resistant to fluoroquinolones.33 
Similar results were noted in another study in which, overall, 
96.2% of Gram-positive cocci isolated from bacterial keratitis 
samples (N = 104) were susceptible to gatifloxacin, whereas 
60.4% were susceptible to ciprofloxacin.84 No differences 
in susceptibility were observed among Gram-negative 
isolates.84 Corneal ulcer healing rates with gatifloxacin 
were significantly (P  0.01) higher for infections caused 
by Gram-positive pathogens but not for those caused by 
Gram-negative pathogens, indicating that gatifloxacin may 
be a preferred (albeit off-label) alternative to ciprofloxacin 
as the first-line monotherapy in bacterial keratitis.84
As discussed earlier, higher concentrations of topical 
drugs are achievable in the eye; however, systemic minimum 
inhibitory concentration (MIC) values (CLSI standards) 
continue to be used as the susceptibility breakpoint in 
the treatment of ocular infections. The effect of MIC 
breakpoints on the rate of clinical response of bacterial 
keratitis isolates (N = 663) to ciprofloxacin showed that 
for MIC  1 µg/mL, the cure rate was 74.5% (n = 272), 
but for isolates with MIC  1 µg/mL, the cure rate was 
only 57.7% (n = 15). This could indicate that ciprofloxacin-
resistant bacteria respond slowly to a higher concentration 
of ciprofloxacin,85 that organisms with higher MICs do not 
attain adequate pharmacodynamic goals for treatment, or 
that resistant mutants frequently emerge. Although this study 
may be limited by an inherent overestimation of the level of 
ciprofloxacin susceptibility on response rates, susceptibility 
testing of corneal cultures may predict the response of 
bacterial keratitis to fluoroquinolone therapy.85
S. aureus isolated from bacterial keratitis samples 
(N = 177) that was resistant to the older fluoroquino-
lones ciprofloxacin, levofloxacin, and ofloxacin remained 
susceptible to the advanced fluoroquinolones gatifloxacin 
and moxifloxacin.23 The MIC90 for the advanced-generation 
fluoroquinolones was lower than the MIC90 for the older 
agents for all other Gram-positive bacteria tested, indicating 
that the advanced fluoroquinolones exhibited greater 
potency against bacterial keratitis pathogens. Although 
ciprofloxacin still had the lowest MIC90 for Gram-negative 
bacteria, overall the newer fluoroquinolones offer significant 
advantages, especially for Gram-positive bacteria, in the 
treatment of bacterial keratitis.23 In one recent study, how-
ever, P . aeruginosa and S. aureus isolates from 2 cases of 
bacterial keratitis after refractive surgery showed resistance 
to moxifloxacin and gatifloxacin, highlighting the need to 
develop newer anti-infective agents.86
increasing bacterial resistance  
in endophthalmitis and other ocular 
infections
Antimicrobial resistance, including to the advanced-
generation fluoroquinolones, has been identified from endo-
phthalmitis isolates as well. The in vitro cross-resistance of 
gatifloxacin and moxifloxacin versus older fluoroquinolones Clinical Ophthalmology 2009:3 513
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was evaluated among 111 CoNS isolates recovered from 
patients with endophthalmitis over 15 years from January 1, 
1990, through December 31, 2004.87 More than 65% of the 
CoNS isolates resistant to ciprofloxacin (n = 38) also dem-
onstrated in vitro cross-resistance to gatifloxacin (65.8%) 
and moxifloxacin (71.1%), indicating a significant increase 
in ocular pathogen resistance to fluoroquinolones over the 
15-year period.87 Increasing in vitro resistance to gatifloxacin 
and moxifloxacin may have important implications for the 
prevention and treatment of postoperative endophthalmitis 
and reinforce the need to develop new fluoroquinolones.87
Overall, among bacterial isolates from ocular infections, 
MRSA strains increased from 29.5% in 2000 to 41.6% in 
2005 (Figure 1).27 In this study of ocular isolates from more 
than 200 laboratories, fluoroquinolones were consistently 
active against methicillin-susceptible S. aureus (MSSA), 
S. pneumoniae, and H. influenzae but not against more than 
two-thirds of MRSA isolates.27 Moxifloxacin, gatifloxacin, 
levofloxacin, and ciprofloxacin were, respectively, effective 
against 92.1%, 90.2%, 90.6%, and 91.1% of MSSA isolates, 
but only against 27.4%, 29.0%, 26.5%, and 31.6% of MRSA 
isolates.25 In comparison, resistance among P . aeruginosa 
isolates was 10.5% to ciprofloxacin and gentamicin and 
13.2% to gatifloxacin and ofloxacin.27
Similar trends were observed by the Ocular TRUST 
program, which evaluates the annual change of in vitro 
antimicrobial susceptibilities of S. pneumoniae, H. influen-
zae, and S. aureus in national samples of ocular isolates.26 
In this study, 17% of S. aureus isolates were methicillin 
resistant. About 75% to 85% of MRSA isolates were resistant 
to ciprofloxacin, levofloxacin, moxifloxacin, and gatifloxacin; 
64% were resistant to tobramycin; and 91% were resistant to 
azithromycin. Increased in vitro MRSA resistance suggests 
the need to consider newer, more potent anti-infective agents 
when MRSA is a likely pathogen.26 The susceptibility rates of 
MSSA, S. pneumoniae, and H. influenzae to ciprofloxacin and 
levofloxacin varied from year to year, while the susceptibility 
patterns for the newer fluoroquinolones gatifloxacin and moxi-
floxacin in S. pneumoniae remained stable over the 8-year 
period studied (Figure 2).26 The Ocular TRUST 2 surveillance 
study reported that methicillin resistance in staphylococci was 
a marker for multidrug resistance. Susceptibility profiles for 
S. aureus, CoNS, S. pneumoniae, and H. influenzae to different 
ocular antibiotics also showed that newer fluoroquinolones 
were the most consistently active agents across the range 
of ocular pathogens.88 A European study of susceptibility 
to topical antimicrobial agents among 532 ocular pathogens 
found that overall resistance was substantially higher among 
MRSA isolates and lower among MSSA isolates as well 
(Table 2).89
 As is evident from the studies discussed above, the 
increasing resistance of ocular pathogens to antibiotics has 
followed global increases in resistance to systemic antibiotics.71 
These changes have important implications for the selection 
of antibiotic therapy for ocular infections.75 It is important 
to choose antibiotics with rapid bactericidal activity, based 
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on a combination of microbiology (low MIC90 values) and 
pharmacokinetic (PK) and pharmacodynamic (PD) data 
that predict killing of bacteria with limited development of 
pathogen resistance. The advanced-generation fluoroquino-
lones moxifloxacin and gatifloxacin have been efficacious 
for resolving ocular infections but have also been used 
systemically, increasing the chances of ocular pathogens 
having resistance to these agents.75,90–92 Although most of the 
new fluoroquinolones in development are being developed 
for systemic use, ideally newer agents should be specifically 
designed for topical ophthalmic use with an optimized com-
bination of PK and reduced MIC90 (and thus optimized PD) 
versus MRSA isolates for increased efficacy and safety.27,90–92 
Breakpoints specific for topically administered ophthalmic 
antibiotics are needed to better understand resistance among 
ocular pathogens.90–92 Use of effective PD profiles of these 
new drugs to optimize antibiotic administration, maximize 
bactericidal effect, and minimize toxicity can lead to better 
clinical outcomes and prevention of bacterial resistance.93
Importance of pharmacokinetics 
and pharmacodynamics in the 
development of new  
agents in ocular infection therapy
Over the last decade, several lines of research have helped us 
understand the relevance of PD data in the development of 
new antibiotics for ocular infection.93 In preclinical studies, 
for a given organism, PD parameters provide a measurement 
for the rate and extent of bacterial kill and help to provide 
guidance on optimal modes of drug administration and 
reducing antibiotic resistance.93 A key measure for the 
optimization of an antibiotic’s PD is the amount of time 
the free drug remains available at an exposure greater than 
the MIC (T  MIC) for a pathogen, defined as the time-
dependent killing of the pathogen. Another measure for PD 
optimization of an antibiotic is the ratio of area under the 
free-drug concentration time curve (AUC) at 24 hours to 
the MIC (concentration-dependent killing) or AUC:MIC.94 
The maximum concentration of the drug in target tissue 
after a dose (Cmax) compared to MIC (Cmax/MIC) is another 
parameter used to obtain the PD index. The relative importance 
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Table 2 Ocular pathogen susceptibility to topical antimicrobial agents 
(not shown: 36 nonpneumoniae streptococci, 39 miscellaneous)89
Organism (No of isolates) Percentage of resistant pathogensa
  Gati Cipro Oflox Gent Chloram
H. influenzae (83) 0 0 0 0 1.2
S. pneumoniae (70) 0 1.4 0 94.3 7.1
MSSA (123) 0.8 2.4 1.6 1.6 1.6
enterobacteriaceae (60) 3.4 5.1 5.1 8.5 18.6
P. aeruginosa (38) 13.2 10.5 13.2 10.5 100
CoNS (48) 2.1 31.3 31.3 18.8 20.8
MrSA (35) 57.1 91.4 91.4 37.1 2.9
a532 ocular pathogens isolated from ocular infections from 2001 to 2002.
Abbreviations: Gati, gatifloxacin; Cipro, ciprofloxacin; Oflox, ofloxacin; Gent, gentamicin; 
Chloram, chloramphenicol; MSSA, methicillin-susceptible Staphylococcus aureus; CoNS, 
coagulase-negative Staphylococcus; MrSA, methicillin-resistant Staphylococcus aureus.Clinical Ophthalmology 2009:3 515
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of each of the PD parameters to a drug’s antibacterial activity 
varies among antibiotics.94 For the fluoroquinolones, it has 
been estimated that a Cmax:MIC90 ratio of at least 10 and 
an AUC:MIC90 ratio of at least 100 are required to predict 
microbiological and clinical efficacy.95
The PD properties of an antibiotic vary by organism. 
A study of 7 fluoroquinolones compared the AUC:MIC ratio 
with an index based on the time needed after the removal 
of antibiotic for surviving bacteria to resume growth and 
reach 109 CFU/mL bacterial culture growth density.96 The 
AUC:MIC ratio and the antimicrobial effect index (IE) 
were shown to be specific to each fluoroquinolone, with 
moxifloxacin and grepafloxacin having 1.4 times the anti-
staphylococcal effects of ciprofloxacin.96 When comparing 
therapeutically attainable total drug AUCs of fluoroquino-
lones in humans with the IE and the known ciprofloxacin 
susceptibility breakpoint, moxifloxacin, grepafloxacin, 
and trovafloxacin would require smaller AUC:MIC ratios 
to attain the same acceptable antistaphylococcal effect 
as ciprofloxacin, indicating greater potency of the newer 
fluoroquinolones.96
Optimal antibiotic PD may reduce the development of 
resistant mutants. Recent data with the fluoroquinolones 
suggest that a mutant-prevention concentration (MPC) 
may exist for certain organisms, such as S. pneumoniae.97 
Although MPC has not been applied to other classes of 
antibiotics in general, the MPC for fluoroquinolones defines 
the antimicrobial drug concentration threshold that would 
require an organism to possess 2 mutations simultaneously 
for growth in the presence of the drug.29,98 Mutant prevention 
concentration and PD enable a clinician to optimize 
antimicrobial therapy by sustaining an antibiotic’s ability to 
kill organisms while suppressing the emergence of resistant 
subpopulations of organisms.29,99,100
It is possible to extend the duration of antibiotic expo-
sure for the ocular pathogen through the use of topical 
ocular antibiotics since these agents can achieve higher con-
centrations of the drug in the eye than systemic antibiotics. 
Factors that lead to high concentrations in the eye include 
the concentration of the formulation, its lipophilicity, and 
its aqueous solubility.101 To meet the need for differing ocu-
lar concentrations, ophthalmic antibiotics may be available 
in more than one formulation: for example, levofloxacin 
0.5% and 1.5% for bacterial conjunctivitis and keratitis, 
respectively.37,102 However, topical formulations are often 
limited by formulation, such as solubility and stability, and 
by toxicity issues that could make it difficult to achieve 
increased efficacy through higher concentrations.
In light of the increasing antibiotic resistance pattern of 
bacteria worldwide, including resistance to the more potent, 
advanced-generation fluoroquinolones, the development of 
still newer, more potent fluoroquinolones and improvements 
in treatment protocols for ocular infections have become 
more important.
A novel fluoroquinolone under 
investigation for the treatment 
of ocular infections
Fluoroquinolones act by binding and inhibiting 2 enzymes 
involved in the synthesis of bacterial DNA – DNA gyrase 
and DNA topoisomerase IV – and are therefore considered to 
have a dual mechanism of action.103 Newer fluoroquinolones 
such as gatifloxacin and moxifloxacin have potent activity 
against both of these enzymes in both Gram-negative and 
Gram-positive organisms. In contrast, older fluoroquino-
lones, such as ofloxacin and ciprofloxacin, preferentially 
bind DNA gyrase in Gram-negative organisms and topoi-
somerase IV in Gram-positive organisms, leading to the 
potential for resistance to these agents following a single 
mutation in the target enzyme.103 In the newer fluoroqui-
nolones, with strong affinities for both enzymes, double 
mutation of both target enzymes is needed for high-level 
resistance to develop.103
Besifloxacin (Besivance™; Bausch and Lomb Inc., 
Rochester, NY, USA), is a new fluoroquinolone that was 
recently approved by the US Food and Drug Administration 
for the treatment of bacterial conjunctivitis. This agent 
has a unique structure which may increase its potency.104 
Besifloxacin ophthalmic suspension 0.6% has been 
developed exclusively for the treatment of ocular infections, 
reducing the risk of the emergence of resistant strains due 
to prior widespread systemic exposure to that agent.104 
Besifloxacin’s mechanism of action is similar to that of 
other fluoroquinolones in that it kills bacteria through 
inhibition of DNA gyrase and topoisomerase IV.105 Unlike 
older representatives of that drug family, besifloxacin has 
balanced dual activity, inhibiting both enzymes at similar 
as well as lower concentrations. Thus, the inhibition of the 
enzymatic activities of DNA gyrase and topoisomerase 
IV of S. pneumoniae occurs at lower concentrations 
with besifloxacin than with ciprofloxacin, and even 
with moxifloxacin.105 Since both enzymes are targeted 
simultaneously, mutations leading to high-level resistance 
to besifloxacin cannot occur in a single step. While 
mutations that increased the MIC values for besifloxacin Clinical Ophthalmology 2009:3 516
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were found in laboratory strains of E. coli, S. aureus, 
and S. pneumoniae, the increase in MIC was far greater 
for the comparators ciprofloxacin and moxifloxacin.105 
Besifloxacin has been shown to be active in vitro against 
a broad spectrum of pathogens, including the most com-
mon pathogens of bacterial conjunctivitis as well as drug-
resistant isolates (Table 3).76,106
Besifloxacin demonstrated efficacy in an in vivo murine 
infection model and excellent ocular pharmacokinetics in 
rabbits, with ocular mean residence times of 7 hours and 
conjunctival concentrations in excess of the MIC90 for nonre-
sistant ophthalmic isolates for 12 hours following a single 
dose.104 Single doses of besifloxacin administered to rabbit 
eyes maintained high concentrations in tears, conjunctiva, 
and aqueous humor, with mean residence times of 923, 
458, and 422 minutes, respectively.104,107 Compared with 
gatifloxacin and moxifloxacin, besifloxacin demonstrated 
greater exposure in tears and conjunctiva with lower systemic 
concentrations.108 The conjunctival Cmax:MIC90 ratio for 
besifloxacin exceeds 10 for all 8 nonresistant species, and 
the AUC:MIC90 ratio exceeds 100 for all species except 
P. aeruginosa.104 Based on a conjunctival besifloxacin 
Cmax of 63 µg/mL and a predicted (from PK modeling and 
simulations) AUC(0–24 h) of 214 µg.h/mL, 3 times per day (tid) 
dosing of besifloxacin 0.6% for 1 week should attain adequate 
therapeutic AUC:MIC90 ratios and prevent the development of 
2-step resistant mutants.104
In a rabbit model of MRSA-induced endophthalmitis, 
besifloxacin treatment resulted in significant improvement in 
clinical score (reductions in the signs and symptoms of endo-
phthalmitis), while gatifloxacin, levofloxacin, and moxifloxa-
cin were ineffective.109 Besifloxacin also exhibited significant 
dose-dependent inhibition of IL-1β or lipopolysaccharide-
stimulated cytokines in human monocytes, with a com-
parable or better potency than moxifloxacin, indicating 
that besifloxacin may have anti-inflammatory activity.110 
Similarly, besifloxacin significantly inhibited IL-1ß-induced 
release of proinflammatory cytokines in primary human 
corneal epithelial cells in a dose-dependent manner, with a 
comparable or better efficacy compared to moxifloxacin.109 
Table 3 MiC90 values for besifloxacin against common causes of bacterial conjunctivitis76,106
Bacterial strain Besifloxacin:  MIC90 Comparator(s):  MIC90
Susceptible S. aureusa 0.03–0.5 µg/mL N/A
Susceptible S. epidermidisa 0.03–0.5 µg/mL N/A
Susceptible S. pneumoniaea 0.03–0.5 µg/mL N/A
Susceptible H. influenzaea 0.03–0.5 µg/mL N/A
MrSA 0.06 µg/mL N/A
vancomycin-intermediate S. aureus 2 µg/mL N/A
Methicillin/ciprofloxacin-resistant S. aureus 8 µg/mL N/A
Penicillin-resistant S. pneumoniae 0.12 µg/mL N/A
Levofloxacin-resistant S. pneumoniae 2 µg/mL N/A
H. influenzae with β-lactamase production 0.03 µg/mL N/A
β-lactamase–positive, ampicillin-resistant H. influenzae 0.12 µg/mL N/A
Ciprofloxacin-susceptible MSSA 0.06 µg/mL Moxifloxacin: 0.125 µg/mL 
Gatifloxacin: 0.25 µg/mL
Ciprofloxacin-resistant MSSA 2 µg/mL Moxifloxacin: 8 µg/mL 
Gatifloxacin: 8 µg/mL
Methicillin-susceptible S. epidermidis sensitive to ciprofloxacin 0.06 µg/mL Moxifloxacin: 0.125 µg/mL 
Gatifloxacin: 0.25 µg/mL
Methicillin-resistant S. epidermidis sensitive to ciprofloxacin 0.06 µg/mL Moxifloxacin: 0.125 µg/mL 
Gatifloxacin: 0.25 µg/mL
S. aureus parC S80Y + gyrA S84L double mutant 0.5 µg/mL Moxifloxacin: 0.5 µg/mL 
Ciprofloxacin: 32 µg/mL
S. pneumoniae parC S79Y + gyrA S81Y double mutant 1 µg/mL Moxifloxacin: 4 µg/mL 
Ciprofloxacin: 64 µg/mL
aUnpublished data Bausch & Lomb inc.
Abbreviations: MrSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible Staphylococcus aureus.Clinical Ophthalmology 2009:3 517
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Although the clinical significance of anti-inflammatory 
activity has not been established, reducing inflammation 
associated with infections may enhance drug access to ocular 
tissue and reduce tissue damage.109,110
Human subjects (N = 64) administered a single-dose 
of besifloxacin ophthalmic suspension 0.6% in both eyes 
had mean tear AUC:MIC ratios (24 hours) ranging from 
2464 to 20,533 for S. aureus, S. pneumoniae, S. epidermidis, 
and H. influenzae.111 On average, besifloxacin concentrations 
of 1.6 µg/g or higher were sustained in tears for at least 
24 hours after a single dose.112 These values are greater than 
the MIC90 values for the common ocular pathogens and are 
above the exposure needed to eradicate the organism and 
prevent the development of resistant mutants.111 The PD data 
presented here are therefore indicative of a prolonged and 
effective ocular concentration of the drug. The high AUC:MIC 
ratio over 24 hours reported in this study suggests that the 
extended-release mucoadhesive polymer (DuraSite®; Insite 
Vision, Alameda, CA, USA) used for the besifloxacin oph-
thalmic suspension formulation is an optimal choice for the 
treatment of ocular infections. In this context, formulations 
such as in situ gelling ophthalmic delivery systems have 
also been reported to provide increased bioavailability for 
fluoroquinolones such as gatifloxacin, ciprofloxacin, and 
ofloxacin although it is not clear if or when these products 
may become available in the future.113–115
The efficacy and safety of besifloxacin ophthalmic 
suspension 0.6% was studied in two multicenter, randomized, 
double-masked, vehicle-controlled, parallel-design trials 
with patient populations of 269 and 957. In both trials, the 
efficacy and safety of besifloxacin ophthalmic suspension 
0.6% tid for 5 days was compared with vehicle for the 
complete clinical resolution and eradication of bacterial 
infection.116,117 In the first trial, clinical resolution at the 
primary analysis visit (Day 8) occurred in 73.3% (44/60) 
of besifloxacin-treated patients with culture-confirmed 
conjunctivitis versus 43.1% (25/58) of patients receiving 
vehicle (P  0.001).116 Bacterial eradication occurred in 
88.3% (53/60) of patients in the besifloxacin group versus 
60.3% (35/58) of vehicle-treated patients (P  0.001).116 
In the second trial, clinical resolution at the primary analysis 
visit (Day 5) occurred in 45.2% (90/199) of besifloxacin-
treated patients with culture-confirmed conjunctivitis versus 
33.0% (63/191) of patients receiving vehicle (P = 0.0084), 
while bacterial eradication occurred in 91.5% (182/199) of 
patients in the besifloxacin group versus 59.7% (114/191) 
of vehicle-treated patients (P  0.0001).117 In the first trial, 
the cumulative frequency of ocular adverse events (AEs) 
was similar between the 2 groups116; however, in the second 
trial, the cumulative frequency of ocular AEs was statistically 
greater in the vehicle treatment group (P = 0.0047), due, in 
part, to the higher incidence of conjunctivitis in the vehicle-
treated group.117
A non-inferiority study compared the efficacy and safety 
of besifloxacin and moxifloxacin 0.5% tid for 5 days for 
the treatment of bacterial conjunctivitis (N = 1161, 533 of 
whom had positive cultures).118 Clinical resolution at the 
primary analysis visit (Day 5) occurred in 58.3% and 59.4% 
of patients (besifloxacin and moxifloxacin, respectively; 
P = 0.652; CI, -9.48% to 7.29%), and bacterial eradication 
occurred in 93.3% and 91.1% (besifloxacin and moxifloxacin, 
respectively; P = 0.1238; CI, -2.44% to 6.74%), indicating 
that besifloxacin was non-inferior to moxifloxacin for the 
treatment of bacterial conjunctivitis.118 Besifloxacin was 
well tolerated, with an incidence of AEs that was similar 
to that reported for vehicle or moxifloxacin with no unex-
pected findings.118 Eye irritation was the only ocular AE 
statistically different between treatment groups, occurring 
in 0.3% of subjects on besifloxacin and 1.4% of subjects 
on moxifloxacin (P = 0.0201). The only nonocular AE that 
occurred in more than 1% was headache (1.2% besifloxacin, 
1.6% moxifloxacin).118
Strategies for prevention of antibiotic 
resistance in ocular pathogens
The Centers for Disease Control and Prevention and the 
World Health Organization have proposed strategies to 
preserve the usefulness of antibiotics.119,120 In addition to 
global surveillance programs, adequate training and aware-
ness programs should be implemented.119,120 However, 
surveillance programs must be evaluated with reference 
to the PD data that influence the concentration of an 
antibiotic in the eye. Ocular TRUST data show that cip-
rofloxacin resistance has increased over the past decade.26 
The improved PD properties of the newer generation 
fluoroquinolones help to maximize the concentration of 
the antibiotic at the site of infection and help to reduce 
the incidence of bacterial resistance. Strategies to prevent 
or delay the development of antibiotic resistance among 
ocular pathogens include the prescription of antibiotics 
only when needed and the use of sensitivity testing to 
prescribe the appropriate antibiotic.75 Additional recom-
mended strategies for the prevention of antibiotic resis-
tance are completion of the full course of therapy and the 
decrease in the use of antibiotics for growth promotion 
in animals and agriculture, as well as the development Clinical Ophthalmology 2009:3 518
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of new antibiotic agents with optimized PD.121 Ultimate 
outcomes of treatment depend on efficacy and safety of the 
pharmacotherapy as well as adherence to the established 
guidelines. Prevention of ocular antibiotic resistance 
requires cooperation between patients, physicians (both eye 
care and non-eye care), and the pharmaceutical industry 
to keep current antibiotics effective for a longer time and 
to develop newer antibiotic agents to stay ahead of the 
changing microbial pathogenesis.
Conclusion
Evolving bacterial resistance represents a worldwide 
challenge in the clinical management of infection. 
A parallel increase in resistance among ocular pathogens 
has necessitated transitioning from older to newer, more 
potent antibiotics. In the future, antibiotics for ocular infec-
tions should possess a broad spectrum of activity against 
a wide range of pathogens and be effective and safe to 
use at the optimized PK/PD and MIC90 against resistant 
strains of bacteria.22 Currently, the newer fluoroquinolones 
gatifloxacin and moxifloxacin, and in the near future besi-
floxacin, appear to represent the best choice for treating and 
preventing ophthalmic infections. Agents developed specifi-
cally for ocular use only may help to overcome the evolving 
global antibiotic resistance problem that has resulted from 
inappropriate widespread use of systemic antibiotics.
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